Nivolumab produces durable responses and long-term survival in severe liver cancer patients

April 21, 2017, European Association for the Study of the Liver

Results from the CheckMate 040 study presented today found that nivolumab, an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates, regardless of whether or not patients were infected with Hepatitis B or C. Interim results from the study, presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, showed that the overall objective response rate (ORR) by blinded independent central review (BICR) was 14.5% and ORR by investigator assessment was 19.3% in sorafenib-experienced patients in the dose expansion phase of CheckMate 040. Responses by BICR were ongoing in 71.4% (15/21) of patients, and the 12-month overall survival rate in this cohort was 59.9%. The safety profile of nivolumab was manageable and consistent with that reported in other tumour types.

Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.1,2 The prognosis for patients with advanced cancer is poor,2 and the multikinase inhibitor, sorafenib, is the only approved systemic treatment.3 If the patient is not tolerant or has contraindications for sorafenib therapy, there is currently no standard of care and therefore patients lack effective treatment options.3 Nivolumab has already increased survival time in different types of cancers, and has become an important treatment option for certain types of kidney, blood, melanoma and non-small cell lung cancer.4 Preliminary results from the CheckMate 040 study presented earlier this year suggested that could be an option for the treatment of liver cancer.5 Nivolumab is not yet licensed for HCC in the EU.

"The durable responses and survival rates that were achieved with nivolumab are very welcome, especially as the side effects were manageable," said Prof Bruno Sangro, Head of Liver Unit, Clinica Universidad de Navarra and CIBEREHD, and study author. "These data support the potential of nivolumab in the treatment and stabilisation of advanced liver cancer in those patients who have progressed on sorafenib, with or without chronic viral hepatitis."

The CheckMate 040 study is a Phase 1/2, multi-cohort, open-label study of nivolumab conducted in patients with advanced liver cancer who were not suitable for surgery.6 The primary endpoint of the study was ORR by blinded, independent central review. All 145 patients previously treated with sorafenib in the dose-expansion portion of the study were given intravenous nivolumab 3 mg/kg every 2 weeks until the cancer progressed or side effects became intolerable.

Of the 145 patients who had previously received sorafenib, 132 (91.0%) had progression of their cancer and 12 (8.3%) were intolerant of the therapy. The median follow up was 12.9 months in this interim analysis of the dose expansion phase. The median duration of response (DOR) was not yet reached, and 8/21 responders had a DOR of greater than 12 months. The overall median overall survival (OS) rate was 16.7 months, and it was not reached in those with chronic viral hepatitis B and C. Responses to nivolumab occurred regardless of programmed death-1 (PD-1) ligand expression on tumour cells. Overall, grade 3/4 treatment-related adverse events occurred in 16.6% of patients.

Nivolumab is a programmed-death-1 (PD-1) immune checkpoint inhibitor that is designed to use the body's own immune system to help restore the anti-cancer immune response.5 It restores T-cell-mediated anti-tumour activity so that the T cells recognise and attack cells.5

"The reported median survival of 16.7 months in patients previously treated with is promising and it encourages the evaluation of nivolumab in affected with ," said Prof Alejandro Forner, BCLC group, Liver Unit, Hospital Clinic Barcelona, Spain and member of the EASL Governing Board.

Explore further: Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

More information: Abstract: Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study (GS010), The International Liver Congress 2017.

References:

1 World Health Organization. Cancer. Available from: www.who.int/mediacentre/factsheets/fs297/en/. Last accessed: April 2017.

2 World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Last accessed: April 2017.

3 EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.

4 European Medicines Agency. EPAR summary for the public: Opvido (nivolumab). Available from: www.ema.europa.eu/docs/en_GB/d … 3985/WC500189768.pdf. Last accessed: April 2017.

5 Melero I, et al. Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. J Clin Oncol. 2017;35 (suppl 4S: abstract 226.

6 ClinicalTrials.gov. NCT Identifier: NCT01658878. A study to evaluate the effectiveness, safety and tolerability of nivolumab and the combination nivolumab plus ipilimumab in patients with advanced liver cancer (CheckMate 040). Available from: clinicaltrials.gov/show/NCT01658878. Last accessed: April 2017.

7 Bristol-Myers Squibb. How does OPDIVO work inside my body? Available from: www.opdivo.com/advanced-renal- … ivo/how-opdivo-works. Last accessed: April 2017.

Related Stories

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

Five-year survival rate for nivolumab-treated advanced lung cancer patients much higher than historical rate

April 3, 2017
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data ...

Greater patient selection may be needed for first line nivolumab to improve progression-free survival

October 11, 2016
Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a broad group of patients ...

Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer

March 29, 2017
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers ...

Nivolumab improves the proportion of lung cancer patients alive after more than a year

September 28, 2015
Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based ...

Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma

July 21, 2016
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and results from long-term damage and fibrosis, such as is caused by chronic alcohol abuse and viral-induced hepatitis. Patients with advanced HCC are ...

Recommended for you

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

NEJM reports positive results for larotrectinib against TRK-fusion cancer

February 22, 2018
In 2013, the labs of University of Colorado Cancer Center investigator Robert C. Doebele, MD, PhD, and Dana-Farber Cancer Institute investigator Pasi A. Jänne, MD, PhD reported in Nature Medicine the presence of TRK gene ...

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.